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DOI 10.1016/j.ccr.2009.12.048SUMMARYThe NF-kB activating kinase IKKb suppresses early chemically induced liver tumorigenesis by inhibiting
hepatocyte death and compensatory proliferation. To study IKKb’s role in late tumor promotion and pro-
gression, we developed a transplant system that allows initiated mouse hepatocytes to form hepatocellular
carcinomas (HCC) in host liver after a long latency. Deletion of IKKb long after initiation accelerated HCC
development and enhanced proliferation of tumor initiating cells. These effects of IKKb/NF-kB were cell
autonomous and correlated with increased accumulation of reactive oxygen species that led to JNK and
STAT3 activation. Hepatocyte-specific STAT3 ablation prevented HCC development. The negative crosstalk
between NF-kB and STAT3, which is also evident in human HCC, is a critical regulator of liver cancer devel-
opment and progression.INTRODUCTION
Carcinogenesis, consisting of initiation, promotion, and pro-
gression, is a multistage process governed by cumulative
genetic and epigenetic alterations (Nowell, 1976). Tumor initia-
tors induce genetic changes that cause proto-oncogene activa-
tion and/or loss of tumor suppressors (Hennings et al., 1993).
Initiation alone, however, is insufficient for cancer development
and tumor promotion is needed for expansion of initiated cells
into premalignant lesions that progress into malignant tumor
masses. While initiation is brief and irreversible, tumor promo-
tion and progression are long-lasting processes that up to
a point may be reversed, thereby providing a rationale forSignificance
HCC, a leading cause of cancer-related deaths, develops after
much is known about early etiologic events in HCC developme
of premalignant lesions to overt carcinomas. We developed a p
nant progression of chemically induced HCC. Using this system
tocyte survival during early tumor induction, IKKb-driven NF-kB
lation of reactive oxygen species that can lead to activation of
HCC development. An inverse correlation between NF-kB and
286 Cancer Cell 17, 286–297, March 16, 2010 ª2010 Elsevier Inc.chemointervention. Tumor promotion is thought to depend on
an interaction between initiated cells and their microenviron-
ment (Albini and Sporn, 2007) and inflammation is a frequent
tumor promoter (Karin, 2006). Through production of proinflam-
matory cytokines, chemokines, and reactive oxygen species
(ROS), the inflammatory microenvironment exerts a constant
evolutionary pressure on initiated cells while supporting their
proliferation and expansion (Coussens and Werb, 2002). Rela-
tive to early tumor promotion, the mechanisms that control
tumor progression and malignant conversion are poorly under-
stood. An improved understanding of these late steps in the
tumorigenic process is of great importance as it has been esti-
mated that most individuals harbor premalignant lesions thatlong latency in the context of viral hepatitis or obesity. While
nt, little is known about mechanisms governing progression
hysiologically relevant transplant system for studying malig-
we found that in addition to its established effect on hepa-
suppresses malignant progression by preventing accumu-
STAT3, an oncogenic transcription factor that is critical for
STAT3 was also found in a major subfraction of human HCC.
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IKKb-STAT3 Crosstalk Controls HCC Progressionnever or rarely progress to full blown neoplasms (Boucher and
Yakovlev, 1997).
One of the slowest cancers to appear and grow is hepatocel-
lular carcinoma (HCC), the third leading cause of cancer-related
death worldwide (Parkin et al., 2001). HCC usually appears
after exposure to liver carcinogens or infection with one of two
hepatitis viruses, HBV or HCV, but its evolution and growth
may take more than 30 years (Bosch et al., 2004; Tong et al.,
1995). HCC frequently develops in the context of hepatosteato-
sis and liver cirrhosis following chronic liver damage due to
oxidative and endoplasmic reticulum stress, accompanied by
inflammation that drives the compensatory proliferation of
surviving hepatocytes (El-Serag and Rudolph, 2007; Parekh
and Anania, 2007; Wang and Weinman, 2006). Cirrhotic livers
contain premalignant lesions ranging from dysplastic foci to
dysplastic hepatocyte nodules (Wanless, 1995). These lesions
are more proliferative than the surrounding parenchyma and
resemble early HCC (Hytiroglou et al., 2007). A small number
of these lesions undergo malignant conversion, whose rate
may be accelerated by environmental factors (Seki et al., 2000;
Takayama et al., 1990). Premalignant lesions are also found in
chemically induced rodent models of HCC (Pitot, 1990), but their
conversion into frank HCC is controversial (Sell and Leffert,
2008). Understanding the molecular mechanisms underlying the
progression and malignant conversion of premalignant lesions is
critical for any effort to slow down or prevent HCC development.
However, animal models for studying HCC progression are
scarce.
In contrast, early steps in the molecular etiology of HCC have
been extensively studied using transgenic or chemically induced
mouse HCC models (Calvisi and Thorgeirsson, 2005; Fausto,
1999). Using the chemical procarcinogen diethylnitrosamine
(DEN) to induce HCC in mice, we made the initially surprising
discovery that hepatocyte-specific ablation of the IKKb subunit
of the IkB kinase (IKK) complex dramatically enhances HCC
induction (Maeda et al., 2005). These findings stand in marked
contrast to the outcome of IKKb deletion in enterocytes, which
prevents development of colitis associated cancer (CAC) (Greten
et al., 2004). Yet, in both HCC and CAC, deletion of IKKb
in myeloid cells (Kupffer cells in the liver and lamina propria
macrophages and dendritic cells in the colon) attenuates tumor
development due to reduced expression of tumor-promoting
cytokines (Greten et al., 2004; Grivennikov et al., 2009; Maeda
et al., 2005). The anti-tumorigenic activity of hepatocyte IKKb
was suggested to be due to induction of NF-kB-dependent pro-
survival and antioxidant genes. Indeed, DEN administration to
hepatocyte IKKb-deficient (IkkbDhep) mice results in elevated
ROS accumulation, hepatocyte death, and compensatory prolif-
eration, all of which are prevented by the antioxidant butylated
hydroxyanisole (BHA) (Kamata et al., 2005; Maeda et al., 2005).
Similar findings were obtained in mice lacking the NEMO/IKKg
regulatory subunit (Nemo/IkkgDhep mice), whose hepatocyte-
specific ablation results in spontaneous liver damage, hepatos-
teatosis, fibrosis, and HCC development, which are all prevent-
able by BHA administration (Luedde et al., 2007). In contrast, in
other mouse models of HCC that depend on chronic inflamma-
tion and not on liver damage and death-driven compensatory
proliferation, hepatocyte IKKb and NF-kB were found to promote
tumor development (Haybaeck et al., 2009; Pikarsky et al., 2004).Under such conditions, NF-kB activation in hepatocytes is
needed for expression of chemokines and cytokines that orga-
nize and maintain an inflammatory microenvironment.
Although DEN administration activates IKK transiently and
does not lead to chronic hepatitis (Maeda et al., 2005), DEN-
induced HCC (dih) depends on production of the NF-kB-regu-
lated cytokine IL-6 by resident Kupffer cells (Naugler et al.,
2007; Sakurai et al., 2008). In this case, Kupffer cells are acti-
vated by IL-1a released by dying hepatocytes and the absence
of parenchymal IKKb enhances IL-6 production. Interestingly,
male mice produce more IL-6 upon DEN administration than
females, and this accounts for the marked male bias in HCC
induction (Naugler et al., 2007). Although it remains to be estab-
lished whether differential IL-6 production accounts for the
gender bias in human HCC, a recent epidemiological study iden-
tified elevated serum IL-6 as a critical and reliable predictor of
progression from HBV-induced hepatitis to HCC (Wong et al.,
2009). Elevated IL-6 also correlates with accelerated progres-
sion from HCV-induced hepatitis to HCC especially in women
(Nakagawa et al., 2009), which produce more IL-6 after meno-
pause (Cioffi et al., 2002). The postmenopausal increase in IL-6
production may explain the delayed onset of HCC in women
relative to men (Chen et al., 2006). IL-6 transduces its signals
via a heterodimeric receptor composed of the cytokine-binding
IL-6R subunit and the gp130 signaling subunit (Kamimura
et al., 2003). Recently, activating gp130 mutations were identi-
fied as the causal event in nonmalignant hepatic adenomas (Re-
bouissou et al., 2009). These mutations activate the Ras-MAPK
pathway and STAT3, an oncogenic transcription factor that is
critical for CAC development (Bromberg and Wang, 2009; Gri-
vennikov et al., 2009).
To further dissect the molecular mechanisms that govern liver
carcinogenesis, here we examine the role of IKKb-driven NF-kB
in HCC progression as well as its relationships with STAT3 in
both dih in mice and human clinical specimens.
RESULTS
A Transplant System for Studying Progression/
Malignant Conversion of Initiated Hepatocytes
To dissociate initiation and early tumor promotion from HCC
progression and malignant conversion, we established an exper-
imental system for studying late events that affect hepatocarci-
nogenesis. We treated C57BL/6 mice with DEN at 15 days of
age and waited for 3 months to allow hepatocyte initiation and
clonal expansion. At that point, hepatocytes were isolated and
transplanted via splenic injection into livers of MUP-uPA trans-
genic mice (Figure 1A). The latter overexpress urokinase-type
plasminogen activator (uPA) in their hepatocytes and are there-
fore subjected to low-grade but continuous liver damage and
regeneration, making them ideal recipients for exogenous hepa-
tocytes (Weglarz et al., 2000). Furthermore, MUP-uPA mice
develop mild liver fibrosis but no HCC by 8 months of age
(Figure S1A, available online). Their livers also exhibit elevated
expression of IL-6 mRNA (Figure S1B) and enhanced ROS accu-
mulation (Figure S1C). All of these changes resemble the micro-
environment within which human liver cancer forms. Within
a month, transplanted hepatocytes marked with green fluores-
cent protein (GFP) formed small islands in the recipient’s liverCancer Cell 17, 286–297, March 16, 2010 ª2010 Elsevier Inc. 287
Figure 1. A Transplant System for Studying HCC Progression
(A) A diagram of experimental protocol. C57BL/6 pups were given a single i.p. injection of DEN (25 mg/kg) when 15 days old. Hepatocytes were isolated
2–3 months later and transplanted into 3-week-old MUP-uPA mice via intrasplenic injection. Recipients were sacrificed 5 months later for liver tumor analysis.
(B) Representative livers of male MUP-uPA mice 5 months after transplantation with hepatocytes from vehicle- or DEN-treated male mice. Liver sections were
stained with H&E and albumin antibody. Scale bars represent 100 mm.
(C) Relative expression of a-fetoprotein mRNA was determined by real-time PCR in liver tumors (tumor) and surrounding nontumor liver (Non-T). n = 4; *p < 0.01
by t test.
(D–G) DEN-treated male (D and E) or female mice (F and G) were used as hepatocyte donors to MUP-uPA recipients of the indicated gender. Tumor incidence
(D and F) and multiplicity (E and G)were determined at 5 months after transplantation. n = 8–10 for each group; *p < 0.01 by t test (E and G) or *p < 0.01 by
chi-square test (D and F). Error bars represent SD. See also Figure S1.
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cytes (Figure S1D). By 5 months after transplantation, male
MUP-uPA mice receiving hepatocytes from DEN-initiated males
developed multiple tumor nodules that were absent in mice
receiving hepatocytes from vehicle-injected mice (Figure 1B)
or in untransplanted MUP-uPA mice (data not shown). The
tumors, which exhibited a typical trabecular HCC structure and
expressed albumin and elevated amounts of the HCC marker
a-fetoprotein (AFP; Figures 1B and 1C), are likely to be derived
from the transplanted DEN-initiated cells. The latter failed to
grow in normal C57BL/6 mice (data not shown), suggesting
that the MUP-uPA liver microenvironment is conducive and
essential for conversion of initiated hepatocytes into HCC.
To further characterize this system and determine its phys-
iological relevance, we examined whether the host gender
affects HCC formation by transplanted hepatocytes. We injected
male and female mice with DEN and transplanted their hepato-
cytes into MUP-uPA hosts of either gender. Five months later,
male recipients of male hepatocytes exhibited at least one
HCC per liver, whereas less than 50% of female recipients of
male hepatocytes bore tumors (Figure 1D). Furthermore, tumor
multiplicity was five times higher in male hosts (Figure 1E).
Even more striking results were obtained with transplanted
female hepatocytes (Figures 1F and 1G). Although fewer tumors288 Cancer Cell 17, 286–297, March 16, 2010 ª2010 Elsevier Inc.were seen in this case, consistent with the gender bias in HCC
induction (Naugler et al., 2007), male hosts of initiated female
hepatocytes exhibited 4-fold higher tumor incidence and nearly
20 times higher tumor multiplicity than female hosts of female
hepatocytes (Figures 1F and 1G). Since MUP-uPA expression
is similar between males and females (Weglarz et al., 2000;
data not shown), these data demonstrate that gender plays a crit-
ical role not only in HCC initiation and early promotion but also in
tumor progression. Removing initiated hepatocytes from the
female microenvironment where they hardly progress into HCC
to a male microenvironment results in a substantial enhance-
ment of HCC development. These findings support the physio-
logical relevance of the transplant system.
Deletion of Ikkb in Initiated Hepatocytes Enhances
Tumorigenic Potential
Next we examined whether the IKKb-NF-kB pathway, which
inhibits DEN-induced (Maeda et al., 2005) and spontaneous
(Luedde et al., 2007) HCC development, most likely by suppress-
ing death-driven compensatory proliferation that occurs during
early tumor promotion (Karin, 2006), also affects progression.
To this end, we gave Ikkbf/f male mice, which express normal
amounts of IKKb, DEN and transferred their initiated hepatocytes
into MUP-uPA mice. After 1 month, male and female hosts were
Figure 2. IKKb Deletion after Initiation
Enhances HCC Formation and Growth
(A–C) Ikkbf/f male pups were DEN initiated and
used as hepatocyte donors into MUP-uPA mice.
IKKb in transplanted hepatocytes was deleted
1 month later by injection of Adv-Cre. Adv-GFP
was used as a control. Mice were sacrificed
4 months later and whole-cell lysates were pre-
pared from dissected HCCs and surrounding non-
tumor livers (NT).
(A) Lysates were gel separated and immunoblot-
ted with the indicated antibodies or used for
measurement of JNK kinase activity by immune-
complex kinase assay. Relative JNK kinase
activity (KA) and ERK phosphorylation in the
different samples were determined by densitom-
etry and the average relative activities (RA) for
each group of samples are indicated.
(B and C) HCCs per liver were counted (B) and
maximal tumor size was measured (C). n = 7–10
for each group; *p < 0.05.
(D and E) Tumor cell proliferation and apoptosis
were determined by PCNA (D) and TUNEL (E)
staining, respectively, of paraffin-embedded liver
sections (n = 10 for each group; *p < 0.05).
(F and G) Ikkbf/f (Cre) and Ikkbf/f/Mx1-Cre (Cre+)
DEN-initiated males were used as hepatocyte
donors to male MUP-uPA recipients. IKKb dele-
tion was accomplished by poly(IC) injection
1 month after transplantation. HCC multiplicity (F)
and maximal sizes (G) were determined 4 months
later (n = 10 for each group; *p < 0.01). Error bars
represent SD. See also Figure S2.
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delete Ikkb in transplanted hepatocytes. Adv infection caused
mild liver injury, indicated by a small elevation in circulating
ALT (Figure S2). Administration of Adv-Cre induced efficient
IKKb deletion (Figure 2A) and resulted in a 3- to 4-fold increase
in tumor multiplicity and size in both male and female recipients
relative to Adv-GFP infection (Figures 2B and 2C). These results
are consistent with the previous observation that inactivation of
IKKb in cultured hepatocytes enhances their proliferation (Koch
et al., 2009).
In addition to complete IKKb deletion, Adv-Cre administration
increased STAT3 and ERK phosphorylation in HCCs relative to
Adv-GFP administration (Figure 2A). However, JNK and c-Jun
expression and JNK kinase activity, which were elevated in
HCCs relative to non-tumor liver tissue, did not show large differ-
ences between IKKb-expressing and non-expressing HCCs.
Ikkb-deleted HCCs contained more proliferating (PCNA-positive)
cells than IKKb-expressing tumors (Figure 2D), but the rate of
HCC apoptosis was not affected by the IKKb status (Figure 2E).
As an alternative approach to delete Ikkb after tumor initia-
tion, we used DEN-initiated Ikkbf/f/Mx1-Cre mice as hepato-
cyte donors. These mice express Cre recombinase from the
interferon-inducible Mx1 promoter (Kuhn et al., 1995), such
that administration of the interferon inducer poly(IC) results in
efficient Ikkb deletion in liver (Maeda et al., 2005). Using this
experimental setup, we deleted Ikkb 1 month after transplanta-
tion. This resulted in a large increase in HCC multiplicity and
size in hosts receiving initiated hepatocytes from Ikkbf/f/Mx1-
Cre donors relative to hosts transplanted with Ikkbf/f hepatocytes(Figures 2F and 2G). These results clearly demonstrate that in
addition to enhancing tumor initiation and/or early promotion,
deletion of Ikkb in initiated hepatocytes augments and/or accel-
erates HCC progression.
Ikkb Deletion Enhances Hepatosphere Formation
and Tumorigenic Potential
To further examine cell-autonomous effects of IKKb in malignant
hepatocytes, we cultured dih from Ikkbf/f mice. Initially, HCC cells
failed to proliferate and gradually died in standard hepatocyte
culture medium (data not shown). Addition of phenobarbital,
a liver tumor promoter (Kaufmann et al., 1988), and EGF over-
came this problem and allowed the derivation of several cell
strains from dih. Three of the strains (dih10–12) expressed
both albumin and AFP, consistent with being derived from
AFP-expressing HCCs (Figure S3A). All dih cells were albumin
positive, suggesting little contamination, if any, with non-paren-
chymal cells (Figure S3B). These cells showed increased PCNA
expression and enhanced STAT3 phosphorylation relative to
primary hepatocytes, but did not exhibit an obvious increase in
gp130 or b-catenin phosphorylation under standard culture
conditions (Figure S3C). Infection of dih cells with Adv-Cre
resulted in nearly complete Ikkb deletion (IkkbD) (Figure 3A). IkkbD
dih cells grew in multilayers and formed spheroids even under
non-confluent conditions, while Ikkbf/f dih cells mainly grew as
monolayers (Figure S3D). When plated onto Petri dishes without
serum, Ikkbf/f dih cells formed a few floating spheroids (hepato-
spheres) that could be passaged in culture to yield secondary
hepatospheres (Figure 3A). Interestingly, IkkbD dih cells formedCancer Cell 17, 286–297, March 16, 2010 ª2010 Elsevier Inc. 289
Figure 3. IKKb Deletion in Initiated Cells Enhance Proliferation and Self-Renewal of HCC Progenitors
(A) dih cell strains from Ikkbf/f mice were cultured and infected with Adv-GFP or Adv-Cre. Whole-cell lysates of infected dih10 cells were immunoblotted for IKKb
(bottom panel). The cells were further cultured without serum on Petri dishes to form hepatospheres (top panels). Numbers of 1 and 2 hepatospheres formed per
100 plated cells were determined (n = 3; *p < 0.05). Scale bars represent 100 mm.
(B) Ikkbf/f dih10 cells were infected with an empty retrovirus (vector) or a retrovirus expressing IkBa super-repressor (SR). Stably transfected cells were selected
and cultured as above and hepatosphere formation was analyzed (n = 3; *p < 0.05).
(C and D) IKKb-expressing (Ikkbf/f) and -deficient (IkkbD) dih10 cells (2.5 3 106 each) were s.c. injected into 8-week-old C57BL/6 mice.
(C) Allograft volume was measured weekly (n = 5; *p < 0.01). Dissected tumors are shown on the right.
(D) BrdU incorporation into tumors was determined (n = 5; *p < 0.05).
(E) Ikkbf/f and IkkbD dih12 cells were labeled with dsRed and 43105 cells were seeded into MUP-uPA mouse livers. Relative amounts of dsRed DNA in transplanted
MUP-uPA livers were determined by real-time PCR 3 weeks after inoculation and normalized to actin DNA as a measurement of cell growth (n = 5; *p < 0.05).
(F) IkkbD dih10 cells were reconstituted with a control vector or wild-type IKKb expression vector and were s.c. injected into 8-week-old C57BL/6 mice. Allograft
volume was measured weekly (n = 5; *p < 0.01).
(G) Ikkbf/f and IkkbD dih10 cells were s.c. injected as above. Starting from day 2, mice were treated daily with MLN120B or vehicle by oral gavage. Tumor volume was
measured weekly (n = 5; p < 0.01, f/f/control versus f/f/MLN by one-way ANOVA). Error bars represent SD. See also Figure S3.
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Figure 4. STAT3 Is Activated in the Absence
of IKKb Independently of JNK
(A) Tumors derived from Ikkbf/f (f/f) and IkkbD (D)
dih10 cells were collected and lysed. Tumor
lysates were examined for JNK kinase activity
(KA) and STAT3 phosphorylation.
(B and C) Ikkbf/f and IkkbD dih10 cells were infected
with lentiviruses expressing either a control
shRNA (control) or shRNAs against mouse Jnk1/
2 (shJnk1/2) and implanted s.c.
(B) Tumor growth was measured (n = 5; p < 0.05,
D/control versus D/shJnk1/2 by one-way ANOVA).
(C) Tumors were collected and lysed. Lysates
were examined for expression and phosphoryla-
tion of the indicated proteins. Error bars represent
SD. See also Figure S4.
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hepatospheres than Ikkbf/f dih cells. Transduction of Ikkbf/f dih
cells with an IkB super-repressor lentivirus (Boehm et al., 2007)
also enhanced hepatosphere formation (Figure 3B), suggesting
that IKKb inhibits hepatosphere formation via NF-kB.
In mammary cancer, spheroid-forming cells were suggested
to be tumor progenitors (Al-Hajj and Clarke, 2004). To test
whether Ikkb deletion in dih cells enhances tumorigenic poten-
tial, we subcutaneously implanted Ikkbf/f and IkkbD dih10 cells
into C57BL/6 mice. IkkbD cells grew more quickly than Ikkbf/f
cells and after 6 weeks formed tumors that were four times larger
than those formed by Ikkbf/f cells (Figure 3C) and had higher
proliferative index (Figure 3D). A similar difference in proliferative
potential between Ikkbf/f and IkkbD dih cells was seen when the
cells were grown in the liver microenvironment: dsRed-labeled
IkkbD dih12 cells formed faster growing HCCs in MUP-uPA livers
than Ikkbf/f dih12 cells (Figure 3E). Conversely, retroviral-medi-
ated reconstitution of IKKb in IkkbD dih10 cells suppressed
tumorigenic growth (Figure 3F). Thus, the effect of Ikkb deletion
on hepatoma growth is reversible. Enhanced tumorigenic growth
of subcutaneously inoculated dih10 cells was also seen upon
treatment of tumor-bearing mice with the specific IKKb inhibitor
MLN120B (Wen et al., 2006). MLN120B enhanced tumorigenic
growth of Ikkbf/f dih cells and not IkkbD cells and its effect was
equivalent to that of Ikkb deletion (Figure 3G). These data
demonstrate that IKKb is an inhibitor of HCC growth and pro-
gression and suggest that its effect is direct and not due to
irreversible genetic alterations.
STAT3 Activity Is Elevated in the Absence of IKKb
Because of ROS-Mediated SHP1/2 Inactivation
To determine how loss of IKKb accelerates tumor growth and
progression, we examined its effect on signaling pathways that
affect hepatocyte proliferation. Subcutaneous tumors formed
by IkkbD dih cells exhibited a tendency toward higher JNK
activity, but the effect was variable (Figure 4A). A more consis-
tent change was increased STAT3 phosphorylation in IkkbD dih
tumors. Despite the variable effect of IKKb on JNK activity in
HCCs and subcutaneous tumors, silencing of JNK1/2 expres-
sion in dih10 cells suppressed their tumorigenic growth (Fig-
ure 4B) and the inhibitory effect was greater in IkkbD cells.
Curiously, silencing of JNK1/2 expression decreased ERK phos-
phorylation in IkkbD tumors, but had no effect on STAT3 phos-
phorylation (Figure 4C).We examined the cause of elevated STAT3 activity in IkkbD
dih cells. In vitro, both IL-6 and IL-22, which are major STAT3
activators in liver (Naugler et al., 2007; Zenewicz et al., 2007),
led to higher STAT3 activity in IkkbD dih cells than in Ikkbf/f
dih cells (Figures S4A and S4B). Conversely, expression of
constitutively active IKKb (IKKbEE) in IkkbD dih cells inhibited
IL-6-induced STAT3 activation (Figure S4C). The IKKb inhibitor
MLN120B also enhanced IL-6-induced STAT3 activation in dih
cells and a human liver cancer cell line (Figure S4D). Enhance-
ment of STAT3 activation required a 24–48 hr preincubation
with MLN120B, suggesting that IKKb regulates STAT3 indi-
rectly. No obvious differences in IL-6 or IL-22 expression
were detected between IKKb-expressing and non-expressing
HCCs (Figure S4E).
Given these results, we considered that increased STAT3
activity in IkkbD dih cells is due to a cell intrinsic effect on the
STAT3 signaling pathway. In support of this, phosphorylation
of JAK2, a Janus kinase involved in IL-6-mediated STAT3 activa-
tion (Kamimura et al., 2003), was enhanced in tumors formed by
IkkbD dih cells relative to Ikkbf/f dih tumors (Figure 5A), suggesting
that elevated STAT3 activation in IkkbD dih cells is the conse-
quence of enhanced JAK2 activity. Indeed, inhibition of JAK2
expression by shRNA reduced IL-6-induced STAT3 activation
in both Ikkbf/f and IkkbD dih cells (Figure S5A). We also examined
other regulators of the JAK2-STAT3 pathway. Expression of
SOCS3, a critical feedback inhibitor of cytokine signaling and
a STAT3 target gene (Auernhammer et al., 1999; Brender et al.,
2001), whose ablation enhances HCC development (Ogata
et al., 2006), was elevated in IKKb-deficient tumors (Figure 5A).
SOCS3 upregulation is likely to be transcriptional because
SOCS3 mRNA was also higher in the absence of IKKb (Fig-
ure S5B). Thus, enhanced JAK2 activation cannot be due to
diminished SOCS3 expression as previously found in the hypo-
thalamus (Zhang et al., 2008).
Other negative regulators of JAK2-STAT3 signaling include the
SH2-containing phosphatases, SHP1 and SHP2 (Valentino and
Pierre, 2006). Tumors derived from dih cells expressed higher
amounts of SHP2 than SHP1, but these were not significantly
affected by IKKb (Figure 5A). However, both SHP1 and SHP2
phosphatase activities were significantly lower in tumors formed
by IkkbD dih cells relative to Ikkbf/f dih tumors (Figure 5B). SHP1
and SHP2 activities in IkkbD tumors were restored upon recon-
stitution with IKKb (Figure S5C). To validate a role for SHP1/2
in regulation of STAT3, we overexpressed SHP2, the moreCancer Cell 17, 286–297, March 16, 2010 ª2010 Elsevier Inc. 291
Figure 5. ROS-Mediated SHP1/2 Inhibition
in IKKb-Deficient HCCs Correlates with
STAT3 Activation and Accelerated Tumor
Growth
(A) Tumors derived from Ikkbf/f (f/f) and IkkbD (D)
dih10 cells were collected and lysed. Tumor
lysates were immunoprecipitated with an anti-
JAK2 antibody and examined for JAK2 tyrosine
phosphorylation with PY20 antibody. Tumor
lysates were also used for immunoblot analyses
with the indicated antibodies.
(B) SHP1 and SHP2 were immunoprecipitated
from the above tumor lysates and their phospha-
tase activities were measured (n = 4; *p < 0.05).
(C) Fresh frozen sections of HCCs from trans-
planted MUP-uPA mice were analyzed for super-
oxide accumulation by dihydroethydine staining.
Fluorescence intensity in several fields was quan-
titated by ImageJ and relative average increases in
fluorescent intensity are shown (n = 3; *p < 0.01).
The scale bar represents 100 mm.
(D–F) Ikkbf/f (f/f) and IkkbD (D) dih10 cells, 2.53 106
each, were s.c. implanted into 8-week-old C57BL/
6 mice. Starting on day 2, the mice were switched
to a diet containing vehicle or BHA (0.7%) for 6
weeks.
(D) Tumors were collected from BHA-treated and
untreated mice and lysed and SHP1/2 phosphatase activities were measured. The data were plotted as SHP1/2 phosphatase activities in IkkbD tumors relative
to activities in Ikkbf/f tumors (n = 4; *p < 0.05).
(E) Tumor lysates were used for determining JNK kinase activity and STAT3 phosphorylation.
(F) Tumor volume was measured weekly (n = 5; p < 0.01, D/ctrl versus D/BHA by one way ANOVA). Error bars represent SD. See also Figure S5.
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sulted in a strong inhibition of IL-6-induced STAT3 phosphoryla-
tion in both Ikkbf/f and IkkbD dih cells (Figure S5D). These results
strongly suggest that reduced SHP1/2 activities in IKKb-defi-
cient HCCs are responsible for the elevated STAT3 activation.
SHP1 and SHP2 are members of the protein tyrosine phos-
phatase (PTP) family (Figure S5E), whose catalytic cysteine is
highly susceptible to oxidation (Meng et al., 2002; Salmeen
et al., 2003). Several PTPs are subject to reversible inactivation
in response to growth factor (Meng et al., 2002) or cytokine-
induced ROS and this inactivation is potentiated in the absence
of NF-kB (Kamata et al., 2005). We therefore examined ROS
accumulation in HCCs and in dih cells. Staining with the
ROS (superoxide) indicator dihydroethydine revealed more ROS
accumulation in HCCs relative to surrounding tissue and IKKb-
deficient HCCs stained stronger than IKKb-expressing HCCs
(Figure 5C). Cultured IkkbD dih cells also accumulated more
ROS both under basal culture conditions and in response to
IL-6 or EGF than Ikkbf/f dih cells and this was reversed by expres-
sion of constitutively active IKKbEE (Figures S5F and S5G). To
examine the role of ROS in reduced SHP1/2 activities and
STAT3 upregulation in IKKb-deficient HCCs, we fed tumor-
bearing mice with BHA, a potent antioxidant (Maeda et al.,
2005). BHA feeding completely restored SHP1/2 phosphatase
activities and reduced JNK activity and STAT3 phosphorylation
in tumors formed by IkkbD dih cells to levels comparable to those
in Ikkbf/f tumors (Figures 5D and 5E). Importantly, BHA consump-
tion reduced IkkbD tumor growth to a level that was similar to that
of Ikkbf/f tumors in untreated mice (Figure 5F). Collectively, these
data suggest that ROS accumulation in IKKb-deficient HCCs is292 Cancer Cell 17, 286–297, March 16, 2010 ª2010 Elsevier Inc.responsible for reduced PTP activity, JNK and STAT3 activation,
as well as accelerated tumor growth.
STAT3 Activity Is Required for HCC Formation
and Growth
To examine the contribution of activated STAT3 to the enhanced
tumorigenic potential of IkkbD dih cells, we treated tumor-
bearing mice with AG490, an inhibitor of STAT3 phosphorylation
(Eriksen et al., 2001). AG490 inhibited the growth of IkkbD subcu-
taneous tumors and had a more modest effect on Ikkbf/f tumor-
igenic growth (Figure S6A). Immunoblot analysis verified that
AG490 inhibited STAT3 phosphorylation regardless of IKKb
status (Figure S6B). A similar effect on tumor growth was
observed with another STAT3 inhibitor, S3I-201 (Figure S6C),
which inhibits STAT3 activation through binding to its SH2
domain (Siddiquee et al., 2007). S3I-201 also inhibited STAT3
phosphorylation (Figure S6D). To more specifically address the
role of STAT3, we silenced its expression in dih cells via lentiviral
expression of a STAT3-specific shRNA (Figure S6E). In sharp
contrast to cells transduced with a control lentivirus encoding
scrambled shRNA that formed subcutaneous tumors, dih cells
transduced with the STAT3 shRNA failed to grow into subcuta-
neous tumors regardless of their IKKb status (Figure 6A).
To further examine the role of STAT3 in HCC development, we
administered DEN to 15-day-old hepatocyte-specific STAT3-
deficient mice (Stat3f/f/Alb-Cre mice = Stat3Dhep) (Figure 6B).
Stat3Dhep mice were markedly resistant to dih development
with more than 6-fold reduction in HCC multiplicity relative
to Stat3f/f mice (Figure 6C). Tumors in Stat3Dhep mice, which
retained their STAT3 deficiency (Figure 6B), were also
Figure 6. STAT3 Is Required for HCC
Formation and Growth
(A) Ikkbf/f (f/f) and IkkbD (D) dih10 cells were
infected with lentiviruses expressing either scram-
bled shRNA (ctrl) or an shRNA against mouse
Stat3 (shStat3). Stably transfected cells were
selected and 2.5 3 106 cells were s.c. implanted.
Tumor growth was measured (n = 5; p < 0.01,
f/f/ctrl versus f/f /shSTAT3; p < 0.01, D/ctrl versus
D/shSTAT3 by one-way ANOVA).
(B–D) Stat3f/f and Stat3Dhep male mice were
injected with 25 mg/kg DEN when 15 days old.
Mice were sacrificed 8 months later and HCC
induction was evaluated.
(B) HCCs and surrounding non-tumor tissues were
collected and lysed and STAT3 expression and
phosphorylation were examined.
(C and D) Tumor multiplicity (n = 10; *p < 0.01) (C)
and maximal tumor sizes (n = 10; *p < 0.05) (D)
were determined.
(E) STAT3 and NF-kB activation in human HCC.
The top panels show representative samples of
nontumor liver tissue and liver tissue containing
HCC were stained with a phospho-STAT3 anti-
body. The bottom panels show adjacent parallel
sections of the same samples shown in the
top panels were stained with a phospho-p65
antibody. The bar graphs present the frequency of phospho-STAT3-positive HCC specimens among all HCCs or among p65-positive and p65-negative
HCCs (*p < 0.05 by chi-square analysis). Error bars represent SD. See also Figure S6 and Table S1.
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derived Stat3f/f dih cells from dih of Stat3f/f mice, but deletion
of STAT3 from these cells by Ad-Cre infection resulted in inhibi-
tion of cell growth and induction of cell death (Figures S6F and
S6G). These data strongly suggest that STAT3 is required for
mouse HCC development, growth, and survival.
We also examined the status of STAT3 activation in more than
50 different human HCC specimens and found that nearly 60%
of them exhibited activated nuclear STAT3, which could not be
detected in non-tumor liver tissue from the same patient
(Figure 6E). As observed previously (Calvisi et al., 2006), STAT3
activation was more pronounced in the more aggressive
tumors (Table S1). We also found that 25% (13/52) of human
HCCs were positive for phospho-p65/RelA, an indicator of
NF-kB activation. However, phospho-p65-positive HCCs were
often negative for activated STAT3. Only 30.8% of phospho-
p65-positive HCCs were positive for activated STAT3, whereas
66.7% of phospho-p65-negative HCCs exhibited activated
STAT3 (Figure 6E). These data show that a major subfraction
of human HCCs exhibits an inverse relationship between
NF-kB and STAT3.
DISCUSSION
We have developed an experimental system based on trans-
plantation of DEN-initiated hepatocytes into MUP-uPA mouse
liver that allows one to examine factors and mechanisms that
affect the progression of initiated, preneoplastic hepatocytes
into full-blown HCC. Using this system, we found that loss of
IKKb in initiated hepatocytes greatly enhances HCC develop-
ment even when IKKb is deleted or inhibited many months after
tumor initiation. Previously, IKKb and its regulatory subunitNEMO/IKKg were found to negatively control HCC development
in models that depend on compensatory proliferation triggered
by chemically induced or spontaneous hepatocyte death and
liver injury (Luedde et al., 2007; Maeda et al., 2005). This inhibi-
tory effect on HCC development was proposed to be exerted
during early tumor promotion and be due to loss of NF-kB pro-
survival activity, which is more severe in Nemo/IkkgDhep than in
IkkbDhep mice (Karin, 2006). The current results, however, show
that IKKb-driven NF-kB also inhibits late tumor promotion and
progression of initiated hepatoma cells through effects on ROS
metabolism that exert a negative control over the STAT3
signaling pathway (Figure 7). STAT3 itself is frequently activated
in human HCCs, especially in aggressive tumors with poor prog-
nosis (Calvisi et al., 2006; Table S1) and we now show that
STAT3 activation is subject to negative regulation by NF-kB
and is essential for HCC induction. The inverse relationship
between NF-kB and STAT3 also applies to a major subfraction
of human HCCs.
The ability to temporally and physically separate tumor initia-
tion, which in our case occurs upon DEN-induced mutagenesis,
from late tumor promotion and malignant progression has been
instrumental to the success of this study. Interestingly, trans-
plantation of DEN-initiated hepatocytes from either a male or
female donor to normal C57BL/6 recipients, as opposed to
MUP-uPA mice, has never given rise to detectable HCCs. These
findings underscore the importance of the microenvironment
and circulatory system in tumor progression and malignant
conversion. Although the exact factors responsible for the
permissive nature of the MUP-uPA liver microenvironment
remain to be determined, it should be noted that MUP-uPA
mice experience chronic low grade liver injury accompanied by
a small, but significant, elevation in IL-6 expression and ROSCancer Cell 17, 286–297, March 16, 2010 ª2010 Elsevier Inc. 293
Figure 7. A Central Role for IKKb and ROS-Controlled STAT3
Signaling in HCC Development
Inactivation of IKKb or other antioxidant defenses in hepatocytes favors ROS
accumulation and leads to oxidative inhibition of PTPs, including SHP1 and
SHP2. This results in activation of JNK and STAT3, which stimulate the prolif-
eration of initiated preneoplastic hepatocytes. This contributes both to early
tumor promotion and HCC progression. In addition, STAT3 activation
suppresses apoptosis in progressing HCCs.
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These are the same kind of changes that accompany the devel-
opment of human HCC.
Using the transplant system, as well as a culture system that
allowed the derivation of the dih cell strains described above,
we found that deletion or inhibition of IKKb in initiated hepato-
cytes or HCC-derived cells increases their proliferative and
tumorigenic potential. The effect is due to loss of NF-kB activity,
because specific NF-kB inhibition through expression of IkB
super-repressor results in a similar effect. Similar findings were
made in squamous cell carcinoma, where NF-kB was shown
to inhibit keratinocyte proliferation and Ras-induced tumorigen-
esis through negative regulation of JNK activity, whose exact
mechanism was not identified (Dajee et al., 2003; Zhang et al.,
2004). We now show that another way through which NF-kB
inhibits proliferation and tumorigenesis is negative regulation of
STAT3 activation. As shown previously for JNK in TNF-a-treated
NF-kB-deficient cells (Kamata et al., 2005), enhanced STAT3
activation in IkkbD cells or tumors is due to oxidative inhibition
of PTPs, whose catalytic cysteine is extremely susceptible to
oxidation (Meng et al., 2002; Salmeen et al., 2003). While
previous work has shown that PTPs are oxidatively inactivated
under rather harsh conditions that favor ROS accumulation,
such as TNF-a-induced cell death (Kamata et al., 2005), the
present work shows that significant PTP inhibition and subse-
quent kinase activation occur under relatively normal conditions,
as long as NF-kB-dependent antioxidant defenses (Kamata
et al., 2005; Pham et al., 2004) are dismantled. The antioxidant
function of NF-kB, which is exerted in part through expression
of ferritin heavy chain and superoxide dismutase 2 (Kamata
et al., 2005; Pham et al., 2004), is particularly important in the
liver, an organ that is heavily engaged in oxidative metabolism.294 Cancer Cell 17, 286–297, March 16, 2010 ª2010 Elsevier Inc.Indeed, the deletion of hepatocyte NEMO/IKKg results in spon-
taneous liver damage, hepatosteatosis, fibrosis, and HCC
formation, all of which can be prevented by administration of
an antioxidant (Luedde et al., 2007).
Although our work demonstrates an essential and critical role
for STAT3 in HCC development and progression, STAT3 has
been known to be critically involved in several other malignan-
cies, including squamous cell carcinoma (Chan et al., 2004) and
CAC (Bollrath et al., 2009; Grivennikov et al., 2009) and JAK2 or
STAT3 inhibitors were found to inhibit the growth of several
human cancers (Hedvat et al., 2009). Notably, we detected
phosphorylated (i.e., activated) STAT3 in approximately 60%
of human HCCs, with STAT3-positive tumors being more
aggressive. These findings are consistent with those of other
studies in which STAT3 was found to be activated in the
majority of HCCs with poor prognosis and not in surrounding
non-tumor tissue or normal liver (Calvisi et al., 2006; Lin
et al., 2009). Expression of the STAT3-activating cytokine IL-6
is elevated in both liver cirrhosis and HCC (Tilg et al., 1992; Tri-
kha et al., 2003) and was recently found to correlate with rapid
progression from viral hepatitis to HCC (Nakagawa et al., 2009;
Wong et al., 2009). In addition, activating mutations in the gene
encoding the gp130 signaling subunit for IL-6 and other cyto-
kine receptors were found to account for benign hepatic
adenomas (Rebouissou et al., 2009). When combined with
a b-catenin activating mutation, these mutations, which result
in STAT3 activation lead to HCC development. Our findings
suggest that NF-kB may also be engaged in negative regulation
of STAT3 in a subfraction of human HCCs as the frequency of
STAT3-positive HCCs is 2-fold lower in NF-kB-positive HCCs
than in NF-kB-negative HCCs. Altogether, there is little doubt
that STAT3 is a key regulator of liver tumorigenesis in mice
and men. Our results suggest that in addition to its role in
early tumor development, where it suppresses apoptosis and
enhances proliferation of preneoplastic cells (Bromberg and
Wang, 2009), STAT3 plays a critical role during tumor progres-
sion when it is activated many months after the HCC-initiating
event caused by DEN exposure. We identified the IKK-NF-kB
axis as a negative regulator of STAT3 activation, but it needs
to be determined how NF-kB activity is downregulated during
human hepatocarcinogenesis and it is necessary to evaluate
its relative contribution to STAT3 activation vis-a-vis the effects
of cytokines and growth factors. We also show that STAT3 can
be activated in response to ROS accumulation and it should
be noted that several of the most prominent HCC risk factors,
including HCV and hepatosteatosis, result in oxidative stress
(El-Serag and Rudolph, 2007; Parekh and Anania, 2007;
Wang and Weinman, 2006).
The present work as well as previous work with IkkbDhep and
Nemo/IkkgDhep mice (Luedde et al., 2007; Maeda et al., 2005;
Sakurai et al., 2006) demonstrate an anti-tumorigenic role for
NF-kB in hepatocytes. However, it was also described that
NF-kB activation promotes hepatocarcinogenesis in Mdr2/
mice, which develop cholestatic hepatitis and eventually liver
cancer (Pikarsky et al., 2004), and in transgenic mice, which
overexpress lymphotoxin ab in their liver (Haybaeck et al.,
2009). Notably in both Mdr2/ and LTab -transgenic mice,
HCC development depends on chronic low-grade inflammation
and no liver injury has been observed either prior to or
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et al., 2004). Most likely, in these models, in contrast to the injury-
driven IkkbDhep+DEN and Nemo/IkkgDhep models, the main func-
tion of NF-kB in hepatocytes is to upregulate the expression of
chemokines needed for recruitment of inflammatory cells that
contribute to the microenvironment in which these tumors
develop. In the Nemo/IkkgDhep model, however, the absence of
hepatocyte NF-kB results in ROS accumulation and its sequela,
chronic liver damage, hepatosteatosis, fibrosis, and eventual
HCC development, whereas in the transplantation model
described above IKKb-deficient and -proficient initiated HCC
cells are placed into a permissive microenvironment created
by chronic proteolytic damage to the liver. In human hepatocar-
cinogenesis, which is mainly caused and promoted by chronic
HCV or HBV infections or by hepatosteatosis, both inflammatory
and injury/repair responses are likely to be involved (Berasain
et al., 2009). In addition, some viruses inhibit NF-kB activation
to facilitate cell killing and avoid immune detection (Roulston
et al., 1999). Therefore, all of the above model systems bear
some relevance to human HCC development, and, given the
complex effects of IKK/NF-kB inhibition, a more attractive and
likely candidate for therapeutic targeting is the STAT3 signaling
pathway.
EXPERIMENTAL PROCEDURES
Mice and HCC Induction
Ikkbf/f mice (Park et al., 2002) were backcrossed into the C57BL/6 background
for at least six generations. Ikkbf/f/Mx1-Cre mice were described previously
(Maeda et al., 2005). MUP-uPA transgenic mice were kindly provided by
E.P. Sandgren, University of Wisconsin-Madison (Weglarz et al., 2000). Stat3D
hep mice were obtained from D.E. Levy at New York University (Lee et al.,
2002). For HCC induction, 15-day-old littermates were injected with 25 mg/
kg DEN (Sigma). DEN-injected mice were sacrificed either 3 months after
DEN injection to be used as hepatocyte donors or maintained for 8 months
to monitor HCC development. All mouse experimental protocols were
approved by the University of California San Diego Animal Care Program,
following National Institutes of Health guidelines. Histology, gene expression,
and cell signaling were analyzed as described previously (Maeda et al., 2005;
Sakurai et al., 2008).
Isolation and Transplantation of Primary Hepatocytes
Primary hepatocytes were isolated from DEN-treated mice as described previ-
ously (Leffert et al., 1979). For transplantation, cell preparations with viability
greater than 80% were used. Three-week-old MUP-uPA transgenic mice
received 1.2 3 105 viable hepatocytes in 30 ml PBS via intrasplenic injection
with a 30-G needle (Weglarz et al., 2000). Transplanted mice were sacrificed
5 months later to monitor HCC development. For deletion of Ikkb in trans-
planted hepatocytes, mice were given 109 pfu of Adv-GFP or Adv-Cre via
the tail vein 1 month after transplantation. Alternatively, Ikkbf/f/Mx1-Cre hepa-
tocytes were transplanted as above and the recipients were given three injec-
tions (250 mg each) of poly(IC) every other day one month after hepatocyte
transplantation.
Human HCC Specimens and Their Analysis
Human HCC specimens were from the Department of Internal Medicine, Divi-
sion of Gastroenterology/Hepatology, Medical University of Vienna. HCC
samples were obtained during liver transplantation from a total of 52 patients
(49 males and 3 females) who had no prior therapy before surgery (Sieghart
et al., 2006). None of the patients was diagnosed with regional lymph node
metastasis and only one patient had distal metastasis at the time of liver trans-
plantation. Sections prepared from paraffin-embedded blocks were stained
with either phospho-STAT3 antibody (Cell Signaling) or phospho-p65 antibody
(Cell Signaling) at a dilution of 1:50. Conditions for use of all antibodies havebeen posted to http://biorating.com. Positive nuclear staining was scored as
follows: ***, large area staining; **, staining of multiple smaller areas; *, staining
of scattered few positive cells. Immunohistochemical staining of HCC speci-
mens as well as retrospective clinical data collection and analysis were
approved by the local ethics committee of the Medical University of Vienna.
Statistical Analysis
Data are presented as means ± SD. Differences in means were analyzed by
Student’s t test and one-way ANOVA. Tumor incidence (%) was analyzed by
chi-square analysis. p values < 0.05 were considered significant.
Additional experimental procedures are available in the Supplemental
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online
at doi:10.1016/j.ccr.2009.12.048.
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